Abeona Therapeutics (ABEO) CFO awarded 133,595 restricted shares

Rhea-AI Filing Summary

Abeona Therapeutics reported an insider equity award to its Chief Financial Officer, Joseph Walter Vazzano. On January 20, 2026, he received 133,595 shares of common stock as restricted stock at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase. According to the disclosure, these restricted shares will vest in three equal installments on January 20, 2027, January 20, 2028, and January 20, 2029. Following this grant, Vazzano directly beneficially owns 587,226 shares of Abeona Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazzano Joseph Walter

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		133,595(1)	A	$0.00	587,226	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029.

	/s/ Joseph Vazzano	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report in this Form 4?

The filing reports that Chief Financial Officer Joseph Walter Vazzano received an award of 133,595 shares of Abeona Therapeutics common stock as restricted stock on January 20, 2026.

How many Abeona Therapeutics (ABEO) shares were granted to the CFO and at what price?

The CFO was granted 133,595 restricted shares of Abeona Therapeutics common stock at a reported price of $0.00 per share, reflecting a stock-based compensation grant.

What is the vesting schedule for the 133,595 restricted shares reported by ABEO?

The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and the remaining one-third on January 20, 2029.

How many Abeona Therapeutics (ABEO) shares does the CFO own after this Form 4 transaction?

After the reported grant, Chief Financial Officer Joseph Walter Vazzano beneficially owns 587,226 shares of Abeona Therapeutics common stock in direct ownership.

Is the Abeona Therapeutics (ABEO) Form 4 transaction a purchase on the open market?

No. The Form 4 shows a transaction code A and a price of $0.00 per share, indicating this is an equity award of restricted stock, not an open-market purchase or sale.

Who is the reporting person in Abeona Therapeutics (ABEO) latest Form 4 filing?

The reporting person is Joseph Walter Vazzano, who serves as the Chief Financial Officer of Abeona Therapeutics.